Compare Amylx Pharmaceuticals Inc (AMLX) vs Workday Inc (WDAY) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Workday (WDAY) trades at $138.95, up 0.44% with a bullish technical signal. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $2.66 versus $2.51, continuing a trend of earnings outperformance. Revenue growth remains robust, projected to reach $9.9B in 2026, while the company maintains high gross margins of 75.77%. Recent news highlights AI-driven product growth with agentic AI ACV tripling year-over-year.

The outlook remains positive with a $157.30 analyst consensus price target representing 13% upside. Key opportunities include AI adoption driving larger expansion deals, while risks involve a pending California lawsuit over AI bias allegations and elevated valuation multiples. Operating cash flow strength at $2.46B supports continued investment in growth initiatives.